Cardiovascular prostheses

• US 9,867,906 B2
• Filed: 12/21/2016
• Issued: 01/16/2018
• Est. Priority Date: 12/16/2011
• Status: Active Grant

• Current Assignee: Elutia Med LLC
• Original Assignee: Cormatrix Cardiovascular, Inc.
• Inventors: Matheny, Robert G
• Primary Examiner(s): Zhang, Yanzhi
• Application Number:
  US15/386,902
• Publication Number:
  US 20170100523A1
• Time in Patent Office: 391 Days
• Field of Search: 424400, 1 1
• CPC Class Codes: A61F 2/0095 Packages or dispensers for prostheses or other implants for intraocular lenses A61F2/1691; for dental surgery A61C19/02
• CPC Class Codes: A61F 2/02 Prostheses implantable into the body closure means for urethra or rectum or for artificial body openings therefor A61F2/0004
• CPC Class Codes: A61F 2/04 Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts A61F2/18, A61F2/20 take precedence; devices, other than stent-grafts, providing patency to, or preventing collapsing of, tubular structures of the body other than stent-grafts, e.g. stents A61F2/82; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95
• CPC Class Codes: A61F 2/042 Urinary bladders
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2002/044 Oesophagi or esophagi or gullets
• CPC Class Codes: A61F 2002/045 Stomach, intestines
• CPC Class Codes: A61F 2002/046 Tracheae
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/21 Acids
• CPC Class Codes: A61L 2300/232 Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2430/20 for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/3633 Extracellular matrix [ECM]
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/58 : Materials at least partially resorbable by the body
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C08L 67/02 : Polyesters derived from dicarboxylic acids and dihydroxy compounds C08L67/06 takes precedence

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

Claims

1. A particulate biomaterial for treating damaged cardiovascular tissue, consisting of:

a plurality of particulate structures, each of said plurality of particulate structures consisting of first and second tissue remodeling inducing components,

said first tissue remodeling inducing component consisting of a particulate extracellular matrix (ECM) component consisting of an ECM composition, said ECM composition consisting of acellular ECM,

said second tissue remodeling inducing component consisting of an ECM-mimicking biomaterial component, said ECM-mimicking biomaterial component consisting of a biomaterial composition, said biomaterial composition consisting of poly(glycerol sebacate),

said particulate ECM component being encased in said poly(glycerol sebacate) component, wherein said plurality of particulate structures comprise an acellular ECM core with a poly(glycerol sebacate) outer layer,

said poly(glyceraol sebacate) component being adapted to modulate degradation of said encased particulate ECM component, wherein each of said plurality of particulate structures exhibits a linear degradation profile in vivo,

said particulate ECM component and said poly(glyceraol sebacate) component being adapted to jointly induce remodeling of damaged biological tissue when delivered thereto,

each of said plurality of particulate structures being further adapted to modulate inflammation of damaged biological tissue and induce regeneration of new tissue and tissue structures with site specific structural and functional properties, when delivered to said damaged biological tissue.

2. The particulate biomaterial of claim 1, wherein said acellular ECM is derived from a mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), mesothelial tissue, placental tissue and cardiac tissue.